Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Tryptamine Therapeutics ( (AU:TYP) ).
Tryptamine Therapeutics Limited has announced a change in the director’s interest, specifically for Jason Carroll, through the allotment of capital raising shares and options. The company has increased its ordinary fully paid shares by 15 million and options by 7.5 million, as approved by shareholders, which reflects a strategic move to bolster its capital structure.
More about Tryptamine Therapeutics
YTD Price Performance: -15.79%
Average Trading Volume: 1,658,752
Technical Sentiment Signal: Buy
Current Market Cap: A$40.85M
For an in-depth examination of TYP stock, go to TipRanks’ Stock Analysis page.